Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD in Japan
Latest Information Update: 29 Dec 2023
At a glance
- Drugs Tolvaptan (Primary)
- Indications Autosomal dominant polycystic kidney disease
- Focus Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 24 Dec 2023 Status changed from active, no longer recruiting to completed.
- 06 Apr 2022 Planned End Date changed from 1 Mar 2023 to 23 Mar 2024.
- 06 Apr 2022 Planned primary completion date changed from 1 Mar 2022 to 31 Aug 2022.